SCHEMBL210539

SCHEMBL210539

COc1ccc(CCNc2ccnc(Cl)n2)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.64
LMNA P02545 2/20 0.55
TSHR P16473 2/20 0.55
APP P05067 2/20 0.55
PTGDR Q13258 1/20 0.53
POLB P06746 4/20 0.51
ATM Q13315 2/20 0.51
KDM4E B2RXH2 3/20 0.50
MAPK1 P28482 2/20 0.50
KMT2A Q03164 2/20 0.50
GLA P06280 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
USP2 O75604 1/20 0.50
MEN1 O00255 1/20 0.50
STAT3 P40763 1/20 0.50
TTR P02766 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
RAD52 P43351 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9008401 0.79 LMNA (0.72) SMN1; SMN2LMNATSHRAPPPOLB
SCHEMBL19182182 0.79 APP (0.63) SMN1; SMN2LMNATSHRAPPPOLB
SCHEMBL27661951 0.78 CYP1A2 (0.54) LMNATSHRMAPK1KMT2AGLA
SCHEMBL4490252 0.77 LMNA (0.66) SMN1; SMN2LMNATSHRAPPPTGDR
SCHEMBL14291615 0.76 LMNA (0.60) SMN1; SMN2LMNATSHRAPPPTGDR
SCHEMBL9008391 0.76 LMNA (0.83) SMN1; SMN2LMNATSHRAPPPOLB
SCHEMBL210977 0.76 SMN1; SMN2 (0.53) SMN1; SMN2LMNATSHRPTGDRKDM4E
SCHEMBL211742 0.76 SMN1; SMN2 (0.53) SMN1; SMN2LMNATSHRAPPPTGDR
SCHEMBL4385626 0.75 ACHE (0.58) SMN1; SMN2LMNAAPPPOLBKDM4E
SCHEMBL6977133 0.74 MAPT (0.57) LMNATSHRMAPK1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 SMN1; SMN2 3557/4885LMNA 1962/4885TSHR 4130/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 SMN1; SMN2 2705/4885LMNA 1851/4885TSHR 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.